IDXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IDXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
IDEXX Laboratories's average Accounts Receivable for the three months ended in Jun. 2024 was $520 Mil. IDEXX Laboratories's Revenue for the three months ended in Jun. 2024 was $1,004 Mil. Hence, IDEXX Laboratories's Days Sales Outstanding for the three months ended in Jun. 2024 was 47.32.
The historical rank and industry rank for IDEXX Laboratories's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, IDEXX Laboratories's highest Days Sales Outstanding was 46.54. The lowest was 38.13. And the median was 40.12.
IDEXX Laboratories's Days Sales Outstanding increased from Jun. 2023 (43.90) to Jun. 2024 (47.32).
The historical data trend for IDEXX Laboratories's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 39.29 | 40.51 | 39.72 | 41.68 | 42.77 |
IDEXX Laboratories Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 43.90 | 45.58 | 46.06 | 45.65 | 47.32 |
For the Diagnostics & Research subindustry, IDEXX Laboratories's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
IDEXX Laboratories's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (400.619 | + | 457.445) | / | 2 ) | / | 3660.953 | * | 365 |
= | 429.032 | / | 3660.953 | * | 365 | ||||
= | 42.77 |
IDEXX Laboratories's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:
Days Sales Outstanding (Q: Jun. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2024 ) | + | Accounts Receivable (A: Jun. 2024 )) | / | count ) | / | Revenue (A: Jun. 2024 ) | * | Days in Period |
= | ( (507.208 | + | 533.606) | / | 2 ) | / | 1003.578 | * | 365 / 4 |
= | 520.407 | / | 1003.578 | * | 365 / 4 | ||||
= | 47.32 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (NAS:IDXX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of IDEXX Laboratories's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
M Anne Szostak | director | C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837 |
Bruce L. Claflin | director | 7035 RIDGE ROAD, HANOVER MD 21076 |
James F Polewaczyk | officer: Corporate Vice President | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Sophie V. Vandebroek | director | 6 OAK MEADOW ROAD, LINCOLN MA 01770 |
George Fennell | officer: CORPORATE VICE PRESIDENT | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Brian P Mckeon | director | IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Jonathan Jay Mazelsky | director, officer: President and CEO | ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Martin Alexander Smith | officer: Executive Vice President | C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Jonathan W Ayers | director, officer: President & CEO | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Michael Lane | officer: Executive Vice President | C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092 |
Irene Chang Britt | director | CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103 |
Samer Abdul Samad | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Lawrence D Kingsley | director | C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062 |
Asha Collins | director | IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
Stuart Essig | director | 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536 |
From GuruFocus
By GuruFocus Research • 05-02-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 08-05-2024
By GuruFocus Research • 03-08-2024
By Business Wire • 07-30-2024
By Business Wire • 02-20-2024
By Business Wire • 08-21-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 05-13-2024
By GuruFocus Research • 05-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.